Collectively, these findings suggest that enhanced Drp1(-/17) expression leads to an energetic phenotype and alters the metabolism of ovarian cancer cells compared to cells expressing Drp1(16/17). This evidence concerns the gene DNM1L and ovarian carcinoma.